Carregant...
Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
Tumour hypoxia has been pursued as a cancer drug target for over 30 years, most notably using bioreductive (hypoxia-activated) prodrugs that target antineoplastic agents to low-oxygen tumour compartments. Despite compelling evidence linking hypoxia with treatment resistance and adverse prognosis, a...
Guardat en:
| Publicat a: | Br J Cancer |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4865974/ https://ncbi.nlm.nih.gov/pubmed/27070712 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.79 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|